U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size & Outlook
Related Markets
U.S. non-alcoholic steatohepatitis biomarkers market highlights
- The U.S. non-alcoholic steatohepatitis biomarkers market generated a revenue of USD 730.3 million in 2024 and is expected to reach USD 2,600.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 23.2% from 2025 to 2030.
- In terms of segment, serum biomarkers was the largest revenue generating type in 2024.
- Hepatic Fibrosis Biomarkers is the most lucrative type segment registering the fastest growth during the forecast period.
Non-alcoholic steatohepatitis biomarkers market data book summary
| Market revenue in 2024 | USD 730.3 million |
| Market revenue in 2030 | USD 2,600.2 million |
| Growth rate | 23.2% (CAGR from 2025 to 2030) |
| Largest segment | Serum biomarkers |
| Fastest growing segment | Hepatic Fibrosis Biomarkers |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
| Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.8% of the global non-alcoholic steatohepatitis biomarkers market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. non-alcoholic steatohepatitis biomarkers market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 251.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-alcoholic Steatohepatitis Biomarkers Market Scope
Non-alcoholic Steatohepatitis Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Prometheus Laboratories Inc. | View profile | 251-500 | San Diego, California, United States, North America | https://www.prometheuslabs.com/ |
| Exalenz Bioscience | View profile | 11-50 | Union, New Jersey, United States, North America | http://www.exalenz.com/ |
| Genfit SA | View profile | 159 | Parc Eurasante, 885, Avenue Eugene Avinee, Loos, France, 59120 | https://www.genfit.com |
| Meridian Bioscience | View profile | 501-1000 | Cincinnati, Ohio, United States, North America | http://meridianbioscience.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
| Siemens AG | View profile | 321000 | Werner-von-Siemens-Strabe 1, Munich, BY, Germany, 80333 | https://www.siemens.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
U.S. non-alcoholic steatohepatitis biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 40.48% in 2024. Horizon Databook has segmented the U.S. non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
A chronic, progressive condition known as NASH causes fatty liver and liver cell damage before progressing to cirrhosis, fibrosis, and Hepatocellular Cancer (HCC). The diagnosis requires a liver biopsy, however, owing to the expense and invasiveness of the procedure, NASH is still underdiagnosed.
To assess liver health, several companies have developed blood- and imaging-based biomarkers, however, neither of these technologies has been systematically evaluated nor validated against the existing gold standard of liver biopsy.
NIMBLE assessed the existing NASH biomarkers to determine those with enough encouraging data to support further validation. These potential biomarkers will be thoroughly investigated by NIMBLE to gauge their effectiveness in comparison with the gold standard and determine whether they are suitable for widespread use in clinical trials, possibly in place of liver biopsy.
Reasons to subscribe to U.S. non-alcoholic steatohepatitis biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. non-alcoholic steatohepatitis biomarkers market databook
-
Our clientele includes a mix of non-alcoholic steatohepatitis biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into U.S. non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. non-alcoholic steatohepatitis biomarkers market size, by end use, 2018-2030 (US$M)
U.S. Non-alcoholic Steatohepatitis Biomarkers Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
